Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug

Trial Profile

Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Mizoribine (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms AMOLED
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 25 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 25 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 25 Jun 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top